Demographics, Baseline Characteristics, and Oncologic Histories of Cohort
| Characteristic | Data* |
| Sex, male/female | 10/15 |
| Age (y) | 58 (25–80) |
| Previous systemic treatment | |
| Chemotherapy | 24 |
| Antiangiogenic agents | 23 |
| Anti-EGFR agents | 13 |
| Previous liver-directed treatment | |
| Partial liver resection | 9 |
| Radiofrequency ablation | 8 |
| External-beam radiotherapy† | 1 |
| ECOG performance status | |
| 0 | 17 |
| 1 | 8 |
| Extrahepatic disease | |
| Pulmonary metastases | 13 |
| Lymph node metastases | 6 |
| Total | 15 |
| Baseline laboratory values | |
| WBC count (109/L) | 7.4 (3.4–12) |
| Platelet count (109/L) | 265 (94–466) |
| Hemoglobin (g/dL) | 12.4 (9.7–15) |
| Serum AST (IU/L) | 37 (11–116) |
| Serum ALT (IU/L) | 39 (13–99) |
| Serum total bilirubin (mg/dL) | 0.5 (0.1–1.7) |
| Serum alkaline phosphatase (IU/L) | 138 (64–713) |
| Serum albumin (g/dL) | 3.5 (2.6–4) |
| Carcinoembryonic antigen (ng/mL) | 33 (1.3–2,213) |
| Liver tumor involvement (%) | 25 (5–60) |
| BSA (m2) | 1.88 (1.37–2.31) |
| Calculated prescribed activity (GBq) | 1.85 (1.07–2.68) |
| Calculated lung shunt (%) | 6.6 (0–13.8) |
| Administered activity (GBq) | 1.69 (0.97–2.33) |
| Liver weight (g) | 1,826 (941–2,958) |
| Whole-liver absorbed dose (DWL) (Gy) | 48.8 (29.8–68.5) |
↵* Qualitative data are expressed as numbers; continuous data are expressed as median and range.
↵† Patient received preoperative chemoradiotherapy for local recurrence of rectal carcinoma. Mean radiation absorbed dose to liver was 4.7 Gy as determined by dose–volume histogram analysis.
ECOG = Eastern Cooperative Oncology Group.